A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine

The U.S. Food and Drug Administration-authorized mRNA- and adenovirus-based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in preventing COVID-19, but they do not induce efficient mucosal immunity or prevent viral transmission. Here, we report the first noninfectious, ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jingen, Jain, Swati, Sha, Jian, Batra, Himanshu, Ananthaswamy, Neeti, Kilgore, Paul B., Hendrix, Emily K., Hosakote, Yashoda M., Wu, Xiaorong, Olano, Juan P., Kayode, Adeyemi, Galindo, Cristi L., Banga, Simran, Drelich, Aleksandra, Tat, Vivian, Tseng, Chien-Te K., Chopra, Ashok K., Rao, Venigalla B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426593/
https://www.ncbi.nlm.nih.gov/pubmed/35900097
http://dx.doi.org/10.1128/mbio.01822-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426593/
https://www.ncbi.nlm.nih.gov/pubmed/35900097
http://dx.doi.org/10.1128/mbio.01822-22

Ejemplares similares